This article only represents the author's own views.
Drug services giant WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) is streamlining its non-core business in China to focus on strengthening its global production base.
The company announced late last month it had agreed to sell two clinical research businesses, WuXi Clinical and WuXi MedKey, to Hillhouse Investment Management for 2.8 billion yuan ($390 million), the latest in a series of disposals that have freed up funds to channel into its international ambitions.
您已閱讀10%（516字），剩余90%（4533字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。